Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
about
Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma.An OX40/OX40L interaction directs successful immunity to hepatitis B virus.Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity.
P2860
Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Immunotherapy Expands and Main ...... iltrating CD8 T Cells In Situ.
@en
type
label
Immunotherapy Expands and Main ...... iltrating CD8 T Cells In Situ.
@en
prefLabel
Immunotherapy Expands and Main ...... iltrating CD8 T Cells In Situ.
@en
P2093
P2860
P356
P1476
Immunotherapy Expands and Main ...... iltrating CD8 T Cells In Situ.
@en
P2093
Amy E Moran
Andrew D Weinberg
Fanny Polesso
P2860
P304
P356
10.4049/JIMMUNOL.1502659
P407
P577
2016-08-08T00:00:00Z